REGENERON PHARMACEUTICALS beat Q1 estimates with adjusted profit of $9.47 per share, though shares fell 6% following lower eye-drug sales. Strong demand for eczema treatment Dupixent offset a 10% decline in Eylea sales, which totaled $941 million. Investors are pivoting focus toward pipeline timelines as Eylea faces rising competition and regulatory delays in the United States.

Dupixent Demand Offsets Eylea Erosion